The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

Inclusion Criteria: * Biopsy confirmation of Breast Cancer * Breast Cancer has continued to grow after having received treatment with an aromatase inhibitor * Postmenopausal women defined as a women who has stopped having menstrual periods * Evidence of hormone sensitivity * Written informed consent to participate in the trial Exclusion Criteria: * Previous treatment with Faslodex (fulvestrant) or Aromasin (exemestane) * Any hormonal therapy used to modify the course of an additional medical condition after prior treatment with a non-steroidal aromatase inhibitor * Treatment with an investigational or non-approved drug within one month * An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures * A history of allergies to any active or inactive ingredients of Faslodex or Exemestane (i.e. castor oil or Mannitol)